MedTrace Logo

First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System

NCT06423690 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-12-10

No results posted yet for this study

Summary

A Prospective, open label, multi center, single arm, First in Human study to assess the safety and initial performance of EAS1 system for Irreversible Electroporation (IRE) ablation of lung cancer in subjects eligible for tumor resection

Conditions

Interventions

DEVICE

EAS1 System

tumor ablation system in IRE method

Sponsors & Collaborators

  • Snipe Medical

    lead INDUSTRY

Principal Investigators

  • Eyal Romem, Dr · Principal investigator at Meir Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-05-15
Completion
2025-07-15

Countries

  • Israel
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06423690 on ClinicalTrials.gov